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Functions of many long noncoding RNAs (lncRNAs)
depend on their ability to interact with multiple
copies of specific RNA-binding proteins (RBPs).
Here, we devised a workflow combining bioinformat-
ics and experimental validation steps to systemati-
cally identify RNAs capable of multivalent RBP
recruitment. This uncovered a number of previously
unknown transcripts encoding high-density RBP
recognition arrays within genetically normal short
tandem repeats. We show that a top-scoring hit in
this screen, lncRNA PNCTR, contains hundreds of
pyrimidine tract-binding protein (PTBP1)-specific
motifs allowing it to sequester a substantial fraction
of PTBP1 in a nuclear body called perinucleolar
compartment. Importantly, PNCTR is markedly over-
expressed in a variety of cancer cells and its downre-
gulation is sufficient to induce programmed cell
death at least in part by stimulating PTBP1 splicing
regulation activity. This work expands our under-
standing of the repeat-containing fraction of the hu-
man genome and illuminates a novel mechanism
driving malignant transformation of cancer cells.
INTRODUCTION
Functions of many lncRNAs, >200-nt-long transcripts lacking
functional open reading frames (ORFs), depend on recruitment
of multiple copies of specific RNA-binding proteins (RBPs) to
repeated cis-elements (Deveson et al., 2017; Quinn and Chang,
2016). For example, a decoy long noncoding RNA (lncRNA)
called NORAD contains at least 17 binding sites for the RBP
Pumilio (Lee et al., 2016; Tichon et al., 2016). Another lncRNA,
Firre, may control nuclear architecture through repeat-mediated
interaction with the nuclear matrix protein hnRNP U (Hacisuley-
man et al., 2014).
Several lncRNAs function as scaffolds facilitating biogenesis
of non-membrane-bound cellular compartments (Chujo and Hir-Molecular Cell 72, 525–540, Nove
This is an open access article undose, 2017; Stanek and Fox, 2017; Sun et al., 2017). A classic
example is the ribosome-producing organelle nucleolus that re-
quires transcription of the 47S/45S rRNA precursors (pre-rRNA)
by the RNA polymerase I for its assembly (Ne´meth and Grummt,
2018). Other structural lncRNAs include NEAT1/MEN-epsilon/
beta nucleating paraspeckles, stress-induced Sat-III transcripts
involved in nuclear stress body assembly and Hsr-omega RNAs
is required to form omega speckles (Chujo and Hirose, 2017;
Stanek and Fox, 2017; Sun et al., 2017). Interestingly, the Sat-III
and the Hsr-omega RNAs contain 160- to 280-nt-long tandem
repeats that may engage in multivalent interactions with corre-
sponding RBPs (Chujo and Hirose, 2017; Stanek and Fox, 2017).
Perhaps the most compelling example of multivalent recruit-
ment of RBPs to RNA is provided by aberrant transcripts ex-
pressed in the context of neurodegenerative and neuromuscular
disorders and containing genetically expanded short tandem re-
peats (STRs), head-to-tail concatemers of 2- to 12-nt sequence
units (Goodwin and Swanson, 2014; Morriss and Cooper, 2017).
For instance, pre-mRNAs containing expanded (CUG)n and
(CCUG)n sequences contribute to pathogenesis of myotonic
dystrophy by sequestering the RBP Muscleblind (MBNL1) in nu-
clear foci and inhibiting its splicing regulation function (Goodwin
and Swanson, 2014; Morriss and Cooper, 2017).
STRs occupy >3% of the reference human genome (Ellegren,
2004). However, with a notable exception of the subtelomeric
repeat-containing lncRNA TERRA, the overall expression status
of endogenously encoded STRs and possible biological func-
tions of the corresponding transcripts remain poorly understood
(Azzalin and Lingner, 2015; Biscotti et al., 2015). Moreover, it is
likely that STR-containing RNAs are underrepresented in the
existing transcriptome annotations because of the inherent diffi-
culty in distinguishing such sequences from their close homo-
logs, especially in the context of RNA sequencing (RNA-seq)
experiments.
LncRNAs and RBPs are frequently deregulated in cancer (Per-
eira et al., 2017; Schmitt and Chang, 2016). For example, poly-
pyrimidine tract-binding protein (PTBP1/PTB/hnRNP I), an RBP
regulating pre-mRNA processing in the nucleus and mRNA
translation in the cytoplasm (Kafasla et al., 2012; Keppetipola
et al., 2012), is upregulated in several types of cancer (Cheung
et al., 2009; He et al., 2014; Wang et al., 2017). This has been
linked with increased proliferation and invasiveness of cancermber 1, 2018 ª 2018 The Author(s). Published by Elsevier Inc. 525
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
cells, as well as their ability to carry out aerobic glycolysis and
evade apoptosis induced by extrinsic cues (Cheung et al.,
2009; Cobbold et al., 2010; David et al., 2010; Izquierdo et al.,
2005; Wang et al., 2017). PTBP1 is also a natural repressor of dif-
ferentiation-specific alternative splicing events (Boutz et al.,
2007; Kafasla et al., 2012; Keppetipola et al., 2012; Makeyev
et al., 2007; Spellman et al., 2007; Yap et al., 2012), providing
another possible explanation for its increased expression in can-
cer cells.
However, upregulation of PTBP1 is insufficient to trigger
cellular transformation on its own (Wang et al., 2008a). Possibly
explaining this paradox, PTBP1 has been shown to stimulate
expression of several activators of apoptosis by either altering
splicing of their pre-mRNAs or increasing their translation effi-
ciency (Bielli et al., 2014; Bushell et al., 2006; Zhang et al.,
2009). How these pro-apoptotic activities are managed in trans-
formed cells overexpressing PTBP1 is an open question. Inmany
cancer cells, a fraction of PTBP1 is recruited to a nuclear body
called perinucleolar compartment (PNC) (Ghetti et al., 1992; Ma-
tera et al., 1995; Norton and Huang, 2013), but the functional sig-
nificance of this effect and the mechanisms directing PTBP1 to
the PNC remain unclear.
Here, we used a combination of bioinformatics and experi-
mental approaches to uncover a number of previously unknown
STR-enriched lncRNAs predicted to recruit multiple copies of
cognate RBPs. An in-depth analysis of one such lncRNA reveals
its critical roles in PNC assembly, regulation of PTBP1 activity,
and cell survival.
RESULTS
Systematic Identification of RNAs Capable of
Multivalent RBP Recruitment
To predict transcripts that may interact with multiple copies of
specific RBPs, we devised a hybrid workflow that reassembles
the transcriptome from RNA-seq data without limiting the contri-
bution of multi-mapping reads and enriches true positives
through a series of bioinformatics filters and experimental valida-
tion steps (Figure 1A; see STARMethods for more detail). Imple-
menting the first two steps of the workflow for five commonly
used human cell lines (A549, HeLa-S3, HepG2, K562, and
MCF7) extended the GENCODE annotation by 17% of newly
predicted transcripts (Figure 1B). Notably, when we examined
transcriptome-wide distribution of RBP motifs, the new tran-
scripts were clearly over-represented (Fisher’s exact test
p = 2.53 1083) among the top hits with Z scores for motif num-
ber and densityR5 (Figure 1B).
Of the newly predicted transcripts, 96 were classified as ‘‘un-
known intergenic RNAs’’ (StringTie class code ‘‘u’’; Table S1).
These tended to have limited protein-coding capacity (Fig-
ure 1C), a feature characteristic for lncRNAs, and an unusually
high STR content (44.1%) exceeding the overall transcriptome
(1.9%) and genome (4.5%) values (Figure 1D). We therefore
termed these transcripts strRNAs. Encouragingly, one strRNA
(strRNA64; Table S1) originated from a subtelomeric region, con-
tained TERRA-like (UUAGGG)n repeats, and was predicted by
our pipeline to interact with hnRNPA1, a known RBP partner of
TERRA (Azzalin and Lingner, 2015). Further searches showed526 Molecular Cell 72, 525–540, November 1, 2018that only four additional strRNAs partially overlapped previously
annotated (but not experimentally characterized) lncRNAs (Table
S1). To the best of our knowledge, the remaining strRNAs have
not been documented previously.
Five strRNAs selected for experimental validation were readily
detectable in HeLa cells using qRT-PCR analyses with three
primer pairs against the 50-proximal, middle and 30-proximal
parts of the predicted transcript sequence (Figure 1E). We also
successfully amplified large STR-containing fragments of these
transcripts using regular RT-PCR and confirmed their identities
by Sanger sequencing (Figures 1E and S1). Amplification of
genomic DNA in the qRT-PCR experiments was ruled out by
including corresponding RT-negative controls (Figure 1E).
Thus, the human genome encodes a number of previously
unknown STR-enriched RNAs with a strong RBP-interaction
potential.
PNCTR Is a Long Transcript Produced by RNA
Polymerase I
One of the newly identified strRNAs (strRNA57) was encoded in
an rDNA intergenic spacer (IGS) and contained numerous
PTBP1-specific motifs (Figure 2A). This suggested an alternative
name for this transcript: pyrimidine-rich noncoding transcript, or
PNCTR. Northern blot analysis with a probe against an STR-
depleted part of PNCTR detected >10-kb-long RNA species in
HeLa cells (Figures 2A and 2B). An 3-kb product was also
visible, but it was substantially less abundant (Figure 2B). The
probe contained a 186-nt sequence 99% complementary to
the IGS28 RNA, an IGS-derived <0.5-kb acidosis-inducible tran-
script (Audas et al., 2012). However, we failed to detect discrete
bands in the corresponding part of the gel suggesting that HeLa
cells do not produce substantial amounts of IGS28 under normal
conditions (Figure 2B).
Two RNA polymerases, pol I and pol II, can generate
PNCTR-sized transcripts. We therefore treated HeLa cells
with the pol-I inhibitor CX-5461 or the pol-II inhibitor 5,6-di-
chloro-1-beta-ribofuranosylbenzimidazole (DRB) and analyzed
the samples by qRT-PCR. CX-5461 inhibited the expression of
PNCTR, whereas DRB increased its abundance (Figures S2A
and S2B). Northern blotting confirmed these results by
showing a dramatic decrease in the intensities of the full-
length and the 3-kb bands in response to CX-5461 (Fig-
ure 2B) and accumulation of the full-length band in the
DRB-treated sample. DRB also reduced the abundance of
the 3-kb product, consistent with the possibility that DRB
might stabilize PNCTR by a yet-to-be-identified mechanism.
As expected for a pol-I transcript, PNCTR did not appear to
be capped or polyadenylated (Figures S2C and S2D). More-
over, analysis of publicly available chromatin immunopre-
cipitation sequencing (ChIP-seq) data confirmed that pol I
can form extensive contacts with PNCTR-encoding IGS se-
quences (Figure S2E).
Overall, this shows that PNCTR occurs predominantly as
a >10-kb-long transcript produced by pol I.
PNCTR Interacts with Multiple Copies of PTBP1 Protein
Predicted PNCTR sequence contains 137 high-quality matches
for the PTBP1-specific position weight matrix defined using an
Figure 1. Identification of strRNAs Enriched in RBP Interaction Motifs
(A) Workflow used in this study.
(B) Transcripts newly predicted by the pipeline in (A) (‘‘new’’) are significantly over-represented among RBP motif-enriched RNAs as compared to previously
annotated (‘‘known’’) transcripts.
(C) strRNAs have significantly shorter ORFs compared to annotated mRNAs and the entire transcriptome.
(D) STR content of strRNAs substantially exceeds corresponding transcriptome and genome values.
(E) qRT-PCR and RT-PCR validation of five newly identified strRNAs using samples prepared without reverse transcriptase (RT) as negative controls. Data are
shown as mean ± SD.
See also Figure S1 and Table S1.
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in vitro selection procedure (Ray et al., 2013) and 2,178 instances
of the YUCUYY and the YYUCUY motifs based on in vivo pat-
terns of PTBP1 binding (Llorian et al., 2010). Since PTBP1 is a
predominantly nuclear protein, we asked whether PNCTR local-
ized in a similar manner. Nuclear and cytoplasmic fractions from
control and DRB-treated HeLa cells (Figure S2F) were analyzed
by RT-PCR with primers designed to amplify three large STR-
containing fragments of PNCTR (RP1–RP3; Figure 2A). The
amplification products were readily detectable in the nuclear,
but not the cytoplasmic, fraction, and their abundance increased
in DRB-treated cells (Figure S2G). All three RT-PCR products
had expected lengths arguing against extensive STR expansion
in this locus in HeLa cells.
As a direct test for PTBP1/PNCTR interaction, we analyzed
HeLa cell lysate by RNA immunoprecipitation (RIP) with a
PTBP1-specific antibody. qRT-PCR analysis of the RIP samples
showed a robust association of PTBP1 with PNCTR (Figure 2C).
PNCTR was immunoprecipitated significantly more efficiently
than the PTBP2 pre-mRNA, a previously characterized PTBP1
target (Keppetipola et al., 2012). Confirming specificity of these
interactions, the U6 small nuclear RNA (snRNA) that lacks
discernable PTBP1 motifs was virtually undetectable in the RIP
fraction. Furthermore, PNCTR and PTBP2 pre-mRNA failed to
immunoprecipitate when we substituted the PTBP1-specific
antibody with a non-immune IgG (Figure 2C).
To further confirm that PTBP1 can interact with PNCTR, we
carried out an electrophoretic mobility shift assay (EMSA) with
an RNA probe containing 0.1-kb PNCTR-derived STR
sequence (Figure 2D). Incubation of the probe with increasing
amounts of purified recombinant PTBP1 gave rise to several
distinct band shifts (S1–S7), whereas no shifts were detected
when we substituted PTBP1 with BSA (Figure 2D). Assuming
that migration of a complex reflects its PNCTR:PTBP1 stoichi-
ometry, it appears that a single molecule of the probe can
interact with R6 PTBP1 molecules (Figure 2D), consistent
with the presence of 6 non-overlapping and 24 overlapping
YUCUYY/YYUCUY motifs in the probe sequence (Figure 2D).
The interaction between PTBP1 and PNCTR was specific since
the complexes failed to form in the presence of increasing
amounts of an unlabeled PNCTR competitor, but not a control
RNA lacking PTBP1-specific motifs (Figure 2E).
Thus, PNCTR is a predominantly nuclear RNA capable of re-
cruiting multiple copies of PTBP1.Figure 2. PNCTR Is a pol-I Transcript Interacting with Multiple Copies
(A) Diagram of the predicted PNCTR locus also showing an adjacent 47S/45S rRN
provisional since different IGS sequences share extensive regions of homology,
(B) Top: northern blot analysis of PNCTR expression in HeLa cells using the probe
lanes were loaded equally.
(C) RIP carried out with a PTBP1-specific antibody or a non-immune IgG control. Im
PNCTR, PTBP2 pre-mRNA (positive control), or U6 snRNA (negative control). Da
t test.
(D) EMSA with purified PTBP1 protein and a PNCTR-specific RNA probe (sequenc
probe with increasing amounts of PTBP1. Bottom left: no band shifts are detect
(E) The PTBP1-PNCTR interaction in (D) is specific since it can be disrupted by i
competitor (top, control RNA sequence; bottom right, the EMSA result).
(F) IF-FISH staining of HeLa cells showing that PNCTR co-localizes with PTBP
Scale bar, 10 mm.
See also Figure S2.PNCTR Localizes to the PNC and Recruits PTBP1 and
Possibly Other Proteins to This Nuclear Body
To gain further insights into PNCTR localization, we co-stained
HeLa cells with an RNA fluorescence in situ hybridization
(FISH) probe spanning the entire PNCTR sequence and
PTBP1-specific antibody. PNCTR signal typically occurred as
one or two prominent dots adjacent to nucleoli (Figure 2F).
PTBP1 immunofluorescence (IF) was detectable throughout
the nucleoplasm but markedly enriched in perinucleolar foci
previously identified as the PNC (Figure 2F; Ghetti et al., 1992;
Matera et al., 1995). Strikingly, the PTBP1 foci showed perfect
co-localization with the PNCTR dots (Figure 2F). Supporting
PNCTR association with the PNC, this strRNA was efficiently
immunoprecipitated with an antibody against another PNC
marker, CELF1/CUGBP1 (Figure S2H; Norton and Huang, 2013).
To test whether PNCTR could recruit PTBP1 to the PNC, we
analyzed cells treated with either CX-5461 or DRB by IF-FISH
(Figure S3A). PNCTR dots virtually disappeared in the presence
of CX-5461 and became noticeably larger after the addition of
DRB (Figure S3A), in line with our biochemical data (Figures
2B, S2A, S2B, and S2G). PTBP1 localization to the PNC was
also diminished byCX-5461 and stimulated byDRB (Figure S3A).
The PNC marker CELF1 followed a similar trend (Figure S3A). Of
note, treating cells with the RNA polymerase-III (pol-III) inhibitor
ML-60218 had a relatively mild effect on the PNC morphology
(Figure S3B).
Importantly, both PNCTR and PTBP1 signals localized to the
PNC became smaller or disappeared when we knocked down
PNCTR using an antisense gapmer oligonucleotide (gmPNCTR)
as compared to a non-targeting gapmer (gmControl; Figures 3A,
3B, and S4A–S4C). When used at its most efficient knockdown
concentration (400 nM; Figure S4A) gmPNCTR resulted in virtu-
ally complete disappearance of the PNCTR and PTBP1 dots
(Figure 3A). The PNCTR and the PTBP1 PNC signals correlated
strongly in both the gmControl (Pearson’s r = 0.88) and the
gmPNCTR samples (r = 0.93) despite the obvious shift of the
latter distribution toward zero (Figure 3C).
As expected, cells treated with a PTBP1-specific siRNA
mixture (siPTBP1) had substantially reduced PTBP1 staining in
the nucleoplasm and the PNC as compared to a non-targeting
siRNA (siControl) (Figures S4D, 3D, and 3E). PNCTR dots also
became somewhat smaller in the siPTBP1-treated cells (Figures
3D and 3E). However, this effect failed to match the extent ofof PTBP1 Protein
A gene and probes used in this study. Mapping to chr21 should be considered
and not all parts of human rDNA have been sequenced.
introduced in (A). Bottom: methylene-blue-stained membrane showing that the
munoprecipitated RNAs were analyzed by qRT-PCR using primers specific to
ta are averaged from three experiments ± SD and compared by a two-tailed
e on the top). Bottom right: multivalent complexes assemble on incubating the
ed when PTBP1 is substituted with BSA.
ncreasing amounts of unlabeled PNCTR probe (bottom left), but not a control
1 in the perinucleolar compartment (PNC). FBL, nucleolar marker fibrillarin.
Molecular Cell 72, 525–540, November 1, 2018 529
(legend on next page)
530 Molecular Cell 72, 525–540, November 1, 2018
PTBP1 depletion from the PNC resulting in markedly reduced
correlation between the sizes of the PTBP1 and the PNCTR
signals in siPTBP1-treated cells (r = 0.32) in comparison with
siControl (r = 0.93) (Figure 3F).
Since PNCTR knockdown also triggered a significant loss of
the PNC-localized CELF1 signal (Figures S4E and S4F), we
concluded that PTBP1 recruitment to the PNC and likely the
overall integrity of this nuclear body depend on PNCTR.
PNCTR Can Sequester a Substantial Amount of PTBP1
We next wondered what fraction of the total PTBP1 pool could
associate with PNCTR. Our qRT-PCR and immunoblot quantifi-
cations estimated that a typical HeLa cell contains36 copies of
the PNCTR RNA and 286,000 copies of the PTBP1 protein l
(Figures S5A–S5C). Given that PNCTR encodes 2,178
YUCUYY/YYUCUY sequences and 565 of them are non-over-
lapping, PNCTR has a capacity to sequester between 27.44%
and 7.12% of cellular PTBP1.
To further validate this prediction, we co-stained HeLa cells
with the anti-PTBP1 antibody and a PNCTR-specific single-
molecule RNA FISH probe set (IF-smFISH). The PNC patterns
generated in this experiment were virtually indistinguishable
from the IF-FISH data above (Figure 4A). However, a closer
inspection of magnified images additionally revealed a few
diffraction-limited smFISH signals clustered around the PNC in
interphase cells or distributed diffusely in cells entering mitosis
(Figure 4B). These spots likely corresponded to individual
PNCTR molecules because they had relatively uniform size
and intensity and often co-localized with PTBP1 IF maxima (Fig-
ures 4B and 4C). By dividing a total smFISH signal by the median
intensity of individual PNCTR molecules we estimated the me-
dian number of PNCTR molecules per interphase nucleus at
45.5 (Figure 4D; 95% confidence interval [CI]: 42.7–49.3), i.e.,
comparable to the qRT-PCR data in Figure S5A.
Robust detection of both PTBP1 and PNCTR using this proto-
col also allowed us to estimate the fraction of PTBP1 co-local-
izing with PNCTR by directly quantifying IF-smFISH images.
This suggested that 7.9% (median value; 95% CI: 7.2%–
8.4%) PTBP1 in HeLa nuclei might interact with PNCTR, and
this value reaches 11.4%–31.2% in the upper quartile of the dis-
tribution (Figure 4E). Overall, this suggests that a substantial
fraction of PTBP1 can occur in a PNCTR-associated form.
PNCTR Is Required for Cell Survival
To elucidate biological function of PNCTR, we examined the ef-
fect of its knockdown on clonogenic potential of HeLa cells (Fig-
ures 5A and 5B). Strikingly, gmPNCTR-treated cultures formedFigure 3. PNCTR Recruits PTBP1 to the PNC
(A) HeLa cells were treated for 24 hr with 400 nM gmControl or gmPNCTR and co
most nuclei, gmPNCTR eliminates PNC-localized signals in both the PNCTR and
(B) Comparison of the dot areas in individual nuclei in (A) using a two-sided Kolm
(C) Two-dimensional density plots summarizing the relationship between PNCTR
(D) HeLa cells were incubated with either siControl or siPTBP1 for 48 hr and analy
both the PTBP1 and the PNCTR signals, but PNCTR is affected to a lesser exten
(E) Comparison of the dot areas in (D) using a two-sided KS test.
(F) Two-dimensional density plots for the relationship between PNCTR and PTB
See also Figures S3 and S4.significantly fewer colonies than gmControl-treated ones (Fig-
ures 5A and 5B). In a time-resolved cell viability assay, growth
of HeLa cultures transfected with gmPNCTR or gmControl was
statistically indistinguishable until 24 hr post transfection (hpt)
(Figures 5C and S5D). However, gmPNCTR-treated cultures
began to lag behind the gmControl-treated ones at 48 and 72
hpt at all three gapmer concentrations tested in this experiment
(Figures 5C andS5D). At itsmost biologically efficient concentra-
tion (400 nM; Figure S4A) gmPNCTR reduced the number of
viable cells beginning from 24 hpt, while the growth curves of
the corresponding gmControl-treated cultures were apparently
normal (Figure 5C). Notably, a virtually complete downregulation
of PNCTR by gmPNCTR occurred by 12 hpt (Figure 5D), i.e., pre-
ceding the viability decline.
To check whether the above effects could be due to pro-
grammed cell death, we repeated the gapmer experiment and
analyzed expression of a key apoptotic factor, cleaved
caspase-3 (CC3), over a 24-hr time period (Figure 5E). A CC3-
specific immunoblot signal became detectable in gmPNCTR-
treated, but not in gmControl-treated, cultures at 12 hpt, and
its intensity further increased by 24 hpt, thus closely matching
the PNCTR downregulation kinetics (Figures 5D and 5E).
Although the p53 pathway is largely attenuated in HeLa cells,
we were able to detect upregulation of this pro-apoptotic tumor
suppressor in gmPNCTR-treated, but not gmControl-treated,
samples using a sensitive enhanced chemiluminescence proto-
col (Figure S5E). Our additional IF analyses showed that
gmPNCTR led to the appearance of CC3-positive cells often
containing pyknotic nuclei, a morphological marker of apoptosis
(Figure 5F). Notably, gmPNCTR induced CC3 less efficiently
when it was introduced into HeLa cells pre-transfected with an
expression plasmid encoding a (UC)n STR-containing PNCTR
fragment lacking gmPNCTR-complementary sequences (Fig-
ures 5G, 5H, and S5F).
Thus, downregulation of PNCTR triggers apoptosis pointing at
its potential pro-survival function.PNCTR Antagonizes PTBP1 Splicing Regulation
Function
We wondered whether the pro-survival activity of PNCTR might
depend on its interaction with PTBP1, a known activator of the
intrinsic branch of apoptosis. To this end, we analyzed possible
changes in HeLa pre-mRNA splicing in response to PNCTR
knockdown (Figure 6A). A number of regulated alternative
splicing events were indeed detected by comparing gmPNCTR-
and gmControl-treated RNA-seq samples using two bioin-
formatics pipelines, ExpressionPlot (Friedman and Maniatis,-stained with a PTBP1-specific antibody and a PNCTR-specific FISH probe. In
PTBP1 channels.
ogorov-Smirnov (KS) test.
and PTBP1 foci in (A).
zed by IF-FISH as in (A). Note that siPTBP1 diminishes the size and intensity of
t than PTBP1. Scale bars in (A) and (D), 10 mm.
P1 foci in (D). Maximal densities in (C) and (F) were set to 1.
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Figure 4. Quantitative Analysis of PTBP1 Sequestration by PNCTR
(A) Co-staining untreated HeLa cells with antibodies against PTBP1 and a PNCTR-specific single-molecule FISH (smFISH) probe set confirms that PNCTR and
PTBP1 co-localize in the PNC. Scale bar, 10 mm.
(B) Inspection of magnified image in (A) additionally reveals individual PNCTR molecules occurring as diffraction-limited spots near the PNC in interphase nuclei
(i1 and i2) or distributed throughout DAPI-positive area in cells entering mitosis (m). Arrowheads mark examples of PNCTR molecules co-localizing with PTBP1.
Scale bar, 1 mm.
(C) Individual PNCTR molecules in (B) give rise to relatively uniform FISH signal intensities.
(D) PNCTR abundance calculated as a ratio between the total PNCTR fluorescence per interphase nucleus in (A) and the median intensity of individual PNCTR
molecules from (C).
(E) Fraction of PTBP1 co-localizing with PNCTR in interphase nuclei in (A). In (C)–(E), solid teal lines show kernel density estimates for the histogram data, and
dashed teal lines mark the medians.
See also Figure S5.2011) and MISO (Katz et al., 2010). Notably, splicing changes
induced by gmPNCTR were enriched among events triggered
by treating HeLa cells with siRNAs against PTBP1 (siPTBP1) or
both PTBP1 and its functionally similar paralog PTBP2
(siPTBP1/2) (Figures 6B, 6C, and S5G). The fold enrichment of
PNCTR-regulated exons among PTBP1-regulated ones
increased when we considered more reliably predicted events
(Figures S5H and S5I). Importantly, overlapping events regulated
in opposite directions (‘‘anti-regulated’’) were significantly en-
riched compared to co-regulated ones (Figures 6D, 6E, and S5J).
We selected five representative examples of anti-regulated
events (Table S3) for RT-PCR validation (Figures 6F, 6G, and
S6A–S6E). In 4 out of the 5 cases including pre-mRNAs of tran-
scriptional regulators BRD8 and RWDD1, a chloride channel532 Molecular Cell 72, 525–540, November 1, 2018(CLCN6) and a pyruvate carboxylase (PC), knocking down
PTBP1 alone (siPTBP1) or in combination with PTBP2
(siPTBP1/2)-stimulated exon inclusion (Figures S6A–S6E). On
the other hand, gmPNCTR progressively increased exon skip-
ping in a concentration-dependent manner, and a similar effect
was achieved by PTBP1 overexpression (Figures S6A and
S6B). gmPNCTR had no detectable effect on the overall
PTBP1 protein levels (Figures S6E and S6F) indicating that
PNCTR knockdown likely increases PTBP1 activity by changing
its cellular localization.
The only example where our routinely used siPTBP1 reagent
was ineffective without siPTBP2 was splicing of the cassette
exon 8 in the pre-mRNA encoding checkpoint kinase 2
(CHEK2; Figures 6F and 6G). However, switching to a more
Figure 5. PNCTR Knockdown Promotes Programmed Cell Death
(A) HeLa cells were transfected with 400 nM gmControl or gmPNCTR and plated at the densities indicated. Note dramatically reduced numbers of colonies in
gmPNCTR-treated wells compared to gmControl.
(B) Colony confluency in (A) quantified from 3 independent transfection experiments and shown as mean ± SD. p values are calculated using a two-tailed t test.
(C) Growth curves of HeLa cells transfectedwith 400 nMgmControl or gmPNCTR show that gmPNCTR leads to a visible decline in cell viability between 24 and 72
hpt. Data are averaged from 6 transfection experiments ± SD and compared by a two-tailed t test.
(D) Time-resolved qRT-PCR analyses showing that gmPNCTR reaches a maximal downregulation effect by 12 hpt. Data are averaged from 3 experiments ± SD.
(E) gmPNCTR, but not gmControl, induces expression of the apoptotic marker cleaved caspase-3 (CC3) at 12–24 hpt.
(F) Dampening PNCTR levels often leads to extensive activation of caspase-3 in HeLa cells (arrowheads). The close up in the top-right corner compares DAPI
staining for a normal nucleus (nN) of a CC3-negative cell and a pyknotic nucleus (pN) of a cell undergoing apoptosis. Scale bars, 10 mm.
(G) CC3 induction by gmPNCTR is less efficient in HeLa cells expressing a gmPNCTR-resistant PNCTR fragment containing (UC)n repeats compared to the
corresponding empty vector control. In (E) and (G), GAPDH is used as a lane-loading control.
(H) GAPDH-normalized CC3 expression levels in (G) averaged from 3 experiments ± SD and compared by a two-tailed t test.
See also Figure S5.potent PTBP1-specific siRNA (siPTBP1#7) or overexpressing a
(UC)n-containing PNCTR fragment reduced exon 8 skipping in
a modest but statistically significant manner (Figures S6G–
S6K). Moreover, treating cells with gmPNCTR or overexpressing
a FLAG-tagged PTBP1 promoted efficient skipping of this exon
(Figures 6F and 6G).
Crosslinking and immunoprecipitation (CLIP)-seq and individ-
ual nucleotide resolution CLIP (iCLIP) data available for HeLa
cells (Coelho et al., 2015; Haberman et al., 2017; Xue et al.,
2009) suggested that the CHEK2 pre-mRNA contains a cluster
of functional PTBP1 binding sites in front of exon 8 (Figure 6H).Importantly, qRT-PCR analyses of UV-cross-linked and partially
fragmented PTBP1-RNA complexes showed a significant in-
crease in PTBP1 occupancy in the exon 8 region in response
to gmPNCTR (Figure 6I; CLIP-CHEK2e8). This was not the
case for an upstream and a downstream region of the CHEK2
pre-mRNA depleted for PTBP1-specific CLIP-seq/iCLIP signals
(Figure 6I; CLIP-CHEK2e2 and CLIP-CHEK2i8). A strong CLIP/
qRT-PCR signal was also detected for a previously described
PTBP1 target, PTBP2 pre-mRNA (Figure 6I; CLIP-PTBP2e10).
However, this interaction was statistically indistinguishable
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Figure 6. PNCTR Antagonizes Splicing Regulation Function of PTBP1
(A) RNA-seq analyses carried out to examine possible role of PNCTR in modulating PTBP1 activity as a regulator of alternative splicing.
(B–E) Fisher’s exact tests showing that gmPNCTR-regulated alternative splicing events are significantly enriched among those regulated by (B) siPTBP1 or (C)
siPTBP1/2, as compared to their occurrence in the entire list of alternative splicing events (Total) considered by ExpressionPlot. Note that alternative events
controlled by both (D) gmPNCTR and siPTBP1 or (E) gmPNCTR and siPTBP1/2 are preferentially regulated in opposite directions (anti-regulated) rather than the
same direction (co-regulated).
(F) Regulation of CHEK2 exon 8 splicing by the PNCTR/PTBP1 circuitry. Left: the two alternative splicing possibilities. Right: RT-PCR analyses of HeLa cells
showing that combined knockdown of PTBP1 and PTBP2 (siPTBP1/2) stimulates exon 8 inclusion, while knockdown of PNCTR (gmPNCTR, 400 nM) or over-
expression of recombinant FLAG-tagged PTBP1 promotes its skipping.
(G) Effects in (F) presented as differences in percent-spliced-in values (DJ; Wang et al., 2008b) between experimental treatments and the corresponding controls.
Positive DJ values indicate an increase and negative, a decrease in exon 8 inclusion. Similar quantifications were also done for cells transfected with 25 and
100 nM gapmers. All data are averaged from 3 experimentally independent comparisons ± SD and analyzed by a paired t test.
(H) CLIP-seq and iCLIP analyses show that PTBP1 forms physical contacts with an extensive array of YUCUYY and YYUCUY motifs in front of CHEK2 exon 8.
Functional significance of the PTBP1 interaction sequence highlighted in gray was validated in the minigene experiment in Figures S6L and S6M.
(I) CLIP/qRT-PCR experiment showing an increase in PTBP1 interaction efficiency with the CHEK2 exon 8 region (CLIP-CHEK2e8) in HeLa cells treated with
gmPNCTR and a lack of this effect for an upstream (CLIP-CHEK2e2) and a downstream region (CLIP-CHEK2i8). PTBP2 pre-mRNA exon 10 region
(legend continued on next page)
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(Figure 6I). Functional importance of the PTBP1-specific motifs
preceding CHEK2 exon 8 was further confirmed by our minigene
experiments (Figures S6L and S6M).
These data strongly suggest that PNCTR functions as a
regulator of splicing antagonizing a specific subset of PTBP1-
controlled events.
PNCTR/PTBP1 Circuitry Controls the Onset and
Progression of Apoptosis
CHEK2 regulates important cellular decisions and, depending on
circumstances, it can either promote or inhibit apoptosis (Zannini
et al., 2014). Since skipping of exon 8 is predicted to truncate
CHEK2 protein or/and destabilize its mRNA through nonsense-
mediated decay (NMD) (Figure 6F), we hypothesized that the
PNCTR/PTBP1 circuitry can control CHEK2 expression levels.
Indeed, transfecting HeLa cultures with gmPNCTR for 24 hr
decreased CHEK2 protein level 2-fold (p = 3.7 3 103)
compared to gmControl (Figure 6J).
To test whether reduced expression of CHEK2 couldmodulate
gmPNCTR-induced apoptotic program, we pre-treated HeLa
cells with either CHEK2-specific (siCHEK2) of control siRNAs
(siControl) for 36 hr and then transfected the same cultures
with gmPNCTR and gmControl for 12 hr, i.e., a time period suf-
ficient for complete downregulation of PNCTR but insufficient
for gmPNCTR to activate CC3 to a full extent (Figure 6K).
Notably, siCHEK2 significantly stimulated CC3 expression in
samples post-transfected with gmPNCTR (Figure 6K) suggest-
ing that downregulation of CHEK2 facilitates gmPNCTR-induced
apoptosis.
Although siCHEK2 failed to upregulate CC3 on its own in Fig-
ure 6K, PTBP1 is known to alter expression of several other reg-
ulators of apoptosis, both at the level of splicing and mRNA
translation (Bielli et al., 2014; Bushell et al., 2006; Izquierdo
et al., 2005; Zhang et al., 2009). We therefore tested whether
increased PTBP1 activity might be sufficient to initiate an
apoptotic response in our experimental system. Gratifyingly,
transfection of HeLa cells with an expression plasmid encoding
a recombinant FLAG-tagged PTBP1 led to a detectable upregu-
lation of CC3 (Figure 6L).
Thus, PNCTR may inhibit apoptosis by limiting cellular PTBP1
activity in general and maintaining adequate expression of
CHEK2 in particular.
PNCTR Is Often Upregulated in Cancer Cells
Given its pro-survival function we wondered whether PNCTR
might be commonly upregulated in transformed cells. Indeed,
it was >30-fold more abundant in a SV40-transformed human(CLIP-PTBP2e10) and ACTB mRNA are used as a positive and a negative c
experiments ± SD and compared by a two-tailed t test.
(J) Left: immunoblot analysis showing a decrease in the CHEK2 protein levels in H
used as a sample identity marker and GAPDH as a lane-loading control. Right: imm
averaged from 3 experiments ± SD and compared by paired t test.
(K) Left: HeLa cells treated with 50 nM of either siControl or siCHEK2 for 36 hr
analyzed for CC3 expression. Note that the preemptive knockdown of CHEK2 fac
CC3 expression averaged from 6 experiments ± SD and compared by paired t t
(L) Expression of recombinant PTBP1 is sufficient to upregulate CC3 in HeLa cells
Right: GAPDH-normalized CC3 expression averaged from 3 experiments ± SD a
See also Figures S5 and S6 and Table S2.fibroblast line (WI-38 VA-13) as compared to their non-trans-
formed parental line WI-38 (Figure 7A). A normal epithelial cell
line, ARPE-19, expressed somewhat smaller amounts of PNCTR
than WI-38 (Figure 7A). On the other hand, steady-state levels of
PNCTR in HeLa, colorectal carcinoma HCT116, colorectal
adenocarcinoma SW620, and breast adenocarcinoma MCF7
expressed PNCTR were orders of magnitude higher than in
WI-38 and ARPE-19 (Figure 7A).
Expression of other RNAs including 47S/45S and RMRP
(a pol-III transcript known to localize to the PNC; Matera et al.,
1995; Norton and Huang, 2013) did not show an obvious corre-
lation with the cell transformation status (Figure 7A). In line with
earlier reports, PTBP1 was noticeably upregulated in all trans-
formed cell lines, but not nearly to the same extent as PNCTR
(Figure 7A). The qRT-PCR signals in our assays depended on
the presence of RT suggesting that non-transformed cells ex-
press PNCTR at low but detectable level (Figure 7B). Cells ex-
pressing large amounts of PNCTR also had readily detectable
PNCTR- and PTBP1-positive perinucleolar dots (Figures S7A
and S7B). Moreover, PNCTR-specific gapmers triggered robust
caspase-3 activation in HCT116, but not ARPE-19 (Figures S7C
and S7D), consistent with the difference in PNCTR expression
between these cells lines (Figure 7A).
To test whether PNCTR was also upregulated in tumor tis-
sues, we analyzed 5 invasive lung cancer biopsies (grade IIB
and higher) along with patient-matched normal lung controls.
Four out of the 5 tumors expressed PNCTR at a significantly
higher level (p < 0.05; t test) than the controls, and in 3 cases
PNCTR was upregulated >5-fold (Figure 7C). When we
analyzed tissue biopsies available for one of the 5 cases by
RNA-FISH, nuclear PNCTR dots were readily detectable in
metastatic cancer cells, but not in the normal lung tissue (Fig-
ures 7D and 7E).
We finally estimated frequency of cancer-specific PNCTR up-
regulation by analyzing previously published RNA-seq data for
77 patient-matched pairs of lung cancer and normal lung (Ju
et al., 2012). This showed significant upregulation of PNCTR in
cancer samples (p = 6.23 103, Wilcoxon signed-rank test; Fig-
ure S7E). As a control, we also quantified expression of lncRNA
MALAT1 (metastasis-associated lung adenocarcinoma tran-
script 1) known to be frequently upregulated in cancer (Sun
et al., 2017). As expected, MALAT1 levels were significantly
higher in cancer samples than in the matching controls
(p = 8.0 3 107, Wilcoxon signed-rank test; Figure S7F). How-
ever, PNCTR andMALAT1were typically upregulated in different
patients pointing at different mechanisms underlying these ef-
fects (Figure S7F).ontrol, respectively. Data are averaged from two triplicated CLIP/qRT-PCR
eLa cells transfected for 24 hr with gmPNCTR compared to gmControl. CC3 is
unoblot quantification showing GAPDH-normalized CHEK2 expression levels
were post-transfected with 400 nM of gmPNCTR or gmControl for 12 hr and
ilitates induction of CC3 in the gmPNCTR samples. Right: GAPDH-normalized
est.
. Left: immunoblot analysis of control and FLAG-PTBP1-transfected samples.
nd compared by paired t test.
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Figure 7. PNCTR Is Often Upregulated in Cancer Cells
(A) qRT-PCR analyses showing that PNCTR expression is orders of magnitude higher in transformed cells (HeLa, HCT116, SW620, MCF7, and the SV40-
transformed clone VA-13 of the normal lung fibroblast line WI-38) than in their non-transformed counterparts (ARPE-19 andWI-38). The data are averaged from 3
assays ± SD and the expression levels in WI-38 cells were set to 1.
(B) qRT-PCR analyses carried out with and without reverse transcriptase (RT) show that the PNCTR signals in ARPE-19 and WI-38 correspond to bona fide
expression of this strRNA at low but detectable levels.
(C) qRT-PCR comparison of PNCTR expression in five invasive lung cancers and patient-matched normal lung samples (Table S3). Data were obtained using
RqP1 primers, normalized to b-actin, averaged from 3 amplification experiments ± SD and compared by a two-tailed t test.
(D) PNCTR-positive nuclear dots are readily detectable by RNA-FISH in a lymph node metastasis sample collected for the case (a) in (C), but not in the matching
normal lung control.
(E) A close up of the boxed area in (D).
Scale bars in (D) and (E), 10 mm.
See also Figure S7.
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We concluded that increased expression of PNCTR is a recur-
ring phenomenon in cancer cells making this strRNA a promising
candidate for further biomedical studies.
DISCUSSION
Our work uncovers previously unknown STR-enriched tran-
scripts (strRNAs) that may function as endogenous regulators
of RNA metabolism and subcellular compartmentalization.
Similar to the transcripts containing aberrantly expanded STRs
and expressed in the context of neurodegenerative and neuro-
muscular diseases (Goodwin and Swanson, 2014; Morriss and
Cooper, 2017), strRNAs are predicted to form multivalent con-
tacts with cognate RBPs. However, an important distinction is
that strRNAs contain extensive STR sequences encoded in the
reference genome. RT-PCR analyses of five strRNAs expressed
at readily detectable levels in HeLa cells are consistent with the
lack of repeat expansion at the corresponding loci (Figures 1E
and S2G).
We show that one of the strRNAs, PNCTR, recruits multiple
copies of PTBP1 protein to the PNC, a cancer-enriched nuclear
body (Figures 2, 3, and 4). The PNCTR/CELF1 interaction data
(Figures S2H, S3A, S4E, and S4F) further suggest that PNCTR
might function as a multipurpose RBP interaction scaffold,
similar to several previously characterized lncRNAs (Chujo and
Hirose, 2017; Ishizuka et al., 2014; Stanek and Fox, 2017; Wu
et al., 2016).
Given that PNCTR is encoded in an rDNA IGS, it is possible
that the PNC is nucleated at or near the PNCTR transcription
site, in close proximity to the nucleolus assembled at the adja-
cent genomic sequences. This would explain why HeLa cells
typically have one or two PNCs and a larger number of nucleoli
(Figure 2F). Similar transcription site-guided process has been
proposed for assembly of other nuclear bodies relying on struc-
tural lncRNAs, such as paraspeckles, omega speckles, and nu-
clear stress bodies (Chujo and Hirose, 2017; Stanek and Fox,
2017; Sun et al., 2017). Future studies will show whether this
compartmentalization mechanism is more general than currently
thought and whether it might involve other newly identified
strRNAs.
Another direction for future work will be to understand physi-
cochemical mechanisms underlying PNC assembly. The (CUG)
n, (CAG)n and (GGGGCC)n repeats expanded in the context of
degenerative diseases can undergo phase transition as a result
of intermolecular base-pairing (Jain and Vale, 2017). However,
this type of interaction is difficult to envision for PNCTR since
(UC)n does not contain pairs of complementary nucleotides. It
is more likely that PTBP1, an RBP with four RNA-recognition do-
mains (Kafasla et al., 2012; Keppetipola et al., 2012), functions as
a molecular crosslinker in this system. Supporting this possibil-
ity, mixtures of PTBP1 and relatively short (UC)n oligonucleo-
tides have been shown to undergo phase separation in vitro
(Banani et al., 2016). Moreover, PTBP1 knockdown leads to a
modest but statistically significant decrease in the size of PNCTR
dots (Figures 3D and 3E). The ability of PTBP1 to engage in pro-
tein-protein interactions may further enhance its crosslinking
properties and explain PNC localization of other components
including Raver1/2 and some pol-III transcripts (Kafasla et al.,2012; Keppetipola et al., 2012; Matera et al., 1995; Norton and
Huang, 2013).
In addition to its role as a scaffold, PNCTR functions as a
decoy molecule sequestering a fraction of cellular PTBP1 in
the PNC. This mechanism affects only a subset of PTBP1 targets
sensitive to the PTBP1 pool releasable from the PNC depot (Fig-
ures 6 and S6). An important example of this behavior is the
CHEK2 exon 8 preceded by multiple YUCUYY/YYUCUY motifs
that might function as a PTBP1 concentration ‘‘sensor’’ (Figures
6F–6J and S6G–S6M).
Exon 8-dependent changes in CHEK2 protein levels appear to
stimulate the apoptotic program triggered by PNCTR knock-
down (Figures 5 and 6). This might be further facilitated by the
PTBP1-dependent pro-apoptotic events described earlier (Bielli
et al., 2014; Bushell et al., 2006; Zhang et al., 2009). Yet another
PNCTR/PTBP1 target uncovered in our study, BRD8, encodes a
component of the Tip60/NuA4 complex known to control cell
survival (Doyon and Coˆte´, 2004). Thus, PNCTR may act as a
buffer allowing cancer cells to express sufficiently large amounts
of PTBP1 while mitigating the risk of apoptosis. Since PNCTR
knockdown tends to promote stronger caspase-3 activation
than PTBP1 overexpression (e.g., cf. CC3 upregulation in Fig-
ures 6J and 6L), it will be interesting to see whether this strRNA
employs additional, PTBP1-independent mechanisms to pro-
mote cell survival.
The rDNA region encoding PNCTR is also known to give rise to
substantially shorter (<0.5 kb) stress-induced IGS RNAs medi-
ating protein detention in nucleolus (Audas et al., 2012). Although
one of the best-characterized examples of this class of tran-
scripts, the acidosis-inducible IGS28 RNA, was not detectable
under our experimental conditions (Figure 2B), it is possible
that PNCTR is post-transcriptionally processed to generate
other short RNAs transported to the nucleolus. This exciting
possibility will be explored in the future, along with the role that
cell-specific differences in PNCTR turnover might play in regu-
lating its steady-state expression levels. Of note, PNCTR is
relatively short lived even in cancer cells (Figure 5D) suggesting
that the corresponding IGS locus is actively transcribed by pol I
(Figure S2E).
We finally show that PNCTR is upregulated to a remarkable
extent in a wide range of human cancers (Figures 7 and S7) ex-
plaining the widespread occurrence of PNC in malignant tumors
(Norton and Huang, 2013). Perhaps more importantly, this ar-
gues that further work on PNCTR and other strRNAsmay provide
novel insights into disease mechanisms and lead to new thera-
pies and diagnostic approaches.STAR+METHODS
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Doxycycline Sigma Aldrich Cat# D9891
DAPI Thermo Fisher Scientific Cat# D1306
Critical Commercial Assays
PrestoBlue Cell Viability Reagent Thermo Fisher Scientific Cat# A13261
Pierce BCA Protein Assay Kit Thermo Fisher Scientific Cat# 23227
mMESSAGE mMACHINE T7 Kit Thermo Fisher Scientific Cat# AM1344
Amersham Megaprime DNA Labeling Systems GE Healthcare Cat# RPN1606
Nick Translation Mix Sigma-Aldrich Cat# 11745808910
PureLink RNA Mini kit Thermo Fisher Scientific Cat# 12183018A
QIAprep Spin Miniprep Kit QIAGEN Cat# 27106
NucleoSpin Gel and PCR Clean-up kit Macherey-Nagel Cat# 740609.250
Deposited Data
CSHL_RnaSeq_A549_cell_longNonPolyA ENCODE; Nature. 2012
Sep 6;489(7414):101-8.
GEO: GSM767854
CSHL_RnaSeq_A549_cell_longPolyA ENCODE; Nature. 2012
Sep 6;489(7414):101-8.
GEO: GSM758564
CSHL_RnaSeq_HeLa-S3_cell_longNonPolyA ENCODE; Nature. 2012
Sep 6;489(7414):101-8.
GEO: GSM767847
CSHL_RnaSeq_HeLa-S3_cell_longPolyA ENCODE; Nature. 2012
Sep 6;489(7414):101-8.
GEO: GSM765402
CSHL_RnaSeq_HeLa-S3_cytosol_longNonPolyA ENCODE; Nature. 2012
Sep 6;489(7414):101-8.
GEO: GSM767838
CSHL_RnaSeq_HeLa-S3_cytosol_longPolyA ENCODE; Nature. 2012
Sep 6;489(7414):101-8.
GEO: GSM765404
CSHL_RnaSeq_HeLa-S3_nucleus_longNonPolyA ENCODE; Nature. 2012
Sep 6;489(7414):101-8.
GEO: GSM767848
CSHL_RnaSeq_HeLa-S3_nucleus_longPolyA ENCODE; Nature. 2012
Sep 6;489(7414):101-8.
GEO: GSM765403
CSHL_RnaSeq_HepG2_cell_longNonPolyA ENCODE; Nature. 2012
Sep 6;489(7414):101-8.
GEO: GSM758567
CSHL_RnaSeq_HepG2_cell_longPolyA ENCODE; Nature. 2012
Sep 6;489(7414):101-8.
GEO: GSM758575
CSHL_RnaSeq_HepG2_cytosol_longNonPolyA ENCODE; Nature. 2012
Sep 6;489(7414):101-8.
GEO: GSM767840
CSHL_RnaSeq_HepG2_cytosol_longPolyA ENCODE; Nature. 2012
Sep 6;489(7414):101-8.
GEO: GSM758576
CSHL_RnaSeq_HepG2_nucleus_longNonPolyA ENCODE; Nature. 2012
Sep 6;489(7414):101-8.
GEO: GSM767850
CSHL_RnaSeq_HepG2_nucleus_longPolyA ENCODE; Nature. 2012
Sep 6;489(7414):101-8.
GEO: GSM758568
(Continued on next page)
e2 Molecular Cell 72, 525–540.e1–e13, November 1, 2018
Continued
REAGENT OR RESOURCE SOURCE IDENTIFIER
CSHL_RnaSeq_K562_cell_longNonPolyA ENCODE; Nature. 2012
Sep 6;489(7414):101-8.
GEO: GSM758577
CSHL_RnaSeq_K562_cell_longPolyA ENCODE; Nature. 2012
Sep 6;489(7414):101-8.
GEO: GSM765405
CSHL_RnaSeq_K562_cytosol_longNonPolyA ENCODE; Nature. 2012
Sep 6;489(7414):101-8.
GEO: GSM767849
CSHL_RnaSeq_K562_cytosol_longPolyA ENCODE; Nature. 2012
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RNA-seq analysis of control-treated HeLa cells (Ling et al., 2016) SRA: SRX154426
RNA-seq analysis of HeLa cells with PTBP1 single
knockdown
(Ling et al., 2016) SRA: SRX1544260
RNA-seq analysis of HeLa cells with PTBP1 and
PTBP2 double knockdown
(Ling et al., 2016) SRA: SRX1544257
RNA-seq analyses of primary lung cancer samples
and patient-matched controls
(Ju et al., 2012) ENA: PRJEB2784
Pol I (POLR1A) ChIP-seq in immortalized HMEC cells (Sanij et al., 2015) GEO: GSM1544525
PTBP1 CLIP-seq in HeLa cells (Xue et al., 2009) GEO: GSE19323
PTBP1 iCLIP in HeLa cells (Coelho et al., 2015;
Haberman et al., 2017)
ArrayExpress: E-MTAB-3108
RNA-seq comparison of HeLa cells treated with
control or PNCTR-specific gapmers
This study ArrayExpress: E-MTAB-6529
Experimental Models: Cell Lines
Human: HeLa ATCC Cat# CCL-2; RRID: CVCL_0030
Human: MCF7 ATCC Cat# HTB-22; RRID: CVCL_0031
Human: SW620 ATCC Cat# CCL-227; RRID: CVCL_0547
Human: HCT-116 ATCC Cat# CCL-247; RRID: CVCL_0291
Human: A-549 ATCC Cat# CCL-185; RRID: CVCL_0023
Human: WI-38 ATCC Cat# CCL-75; RRID: CVCL_0579
Human: WI-38 VA13 (subline 2RA) ATCC Cat# CCL-75.1; RRID: CVCL_2759
Human: ARPE-19 ATCC Cat# CRL-2302; RRID: CVCL_0145
Oligonucleotides
Negative control A gapmer (gmControl;
50-A*A*C*A*C*G*T*C*T*A*T*A*C*G*C)
QIAGEN Cat# 339516 LG00000002-DFA
PNCTR-specific gapmer (gmPNCTR; design ID:
LG00170744; 50-T*G*A*A*G*T*C*G*A*G*G*A*G*C*T*T)
QIAGEN Cat# 339512 LG00170744-DFA
PNCTR-specific gapmer (gmPNCTR’; design
ID:LG00201955; 50-G*A*C*T*G*T*G*A*C*A*T*A*G*G*T*A
QIAGEN Cat#339512 LG00201955-DFA
ON-TARGET plus non-targeting siRNA (siControl) Dharmacon Cat# D-001810-01-20
Human PTBP1-specific ON-TARGET plus siRNA
(siPTBP1#6)
Dharmacon Cat# J-003528-06
Human PTBP1-specific ON-TARGET plus siRNA
(siPTBP1#7)
Dharmacon Cat# J-003528-07
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Human PTBP1-specific ON-TARGET plus siRNA
(siPTBP1#8)
Dharmacon Cat# J-003528-08
Human PTBP1-specific ON-TARGET plus siRNA
(siPTBP1#9)
Dharmacon Cat# J-003528-09
Human PTBP1-specific ON-TARGET plus siRNA
SMARTpool (siPTBP1)
Dharmacon Cat# L-003528-00-0005
Human PTBP2-specific ON-TARGET plus siRNA
SMARTpool (siPTBP2)
Dharmacon Cat# L-021323-01-0005
Human CHEK2-specific ON-TARGET plus siRNA
SMARTpool (siCHEK2)
Dharmacon Cat# L-003256-00-0005
Assorted DNA oligonucleotides This study/IDT See Table S5
Recombinant DNA
BAC: CTD-2016H21 Thermo Fisher Scientific N/A
BAC: PNCTR FISH probe This study See Table S4
Plasmid: pcDNA3 Thermo Fisher Scientific N/A
Plasmid: pEGFP-N3 Clontech N/A
Plasmid: pEM1032 (Expression plasmid encoding
Flag-PTBP1 and EGFP)
(Yap et al., 2012) N/A
Plasmid: pEM1033 (EGFP control for pEM1032) (Yap et al., 2012) N/A
Plasmid: pEM1380 (probe for EMSA) This study See Table S4
Plasmid: pML154 (T7-PNCTR) This study See Table S4
Plasmid: pML159 (PNCTR fragment expression
plasmid containing pol-I promoter)
This study See Table S4
Plasmid: pBM03 (control vector for pML159) (Grob et al., 2014) N/A
Plasmid: pML287 (WT CHEK2 minigene) This study See Table S4
Plasmid: pML291 (mut1 CHEK2 minigene) This study See Table S4
Plasmid: pML292 (mut2 CHEK2 minigene) This study See Table S4
Software and Algorithms




TopHat2 (Version 2.1.0) (Kim et al., 2013) https://ccb.jhu.edu/software/tophat/
index.shtml
HISAT2 (Version 2.1.0) (Kim et al., 2015) http://ccb.jhu.edu/software/hisat2/
index.shtml
StringTie (Version 1.3.3b) (Pertea et al., 2015) https://ccb.jhu.edu/software/stringtie/
Kallisto (Version 0.43.0) (Bray et al., 2016) https://pachterlab.github.io/kallisto/about
Bedtools (Version 2.25.0) (Quinlan and Hall, 2010) https://bedtools.readthedocs.io/en/latest/
Samtools (Version 1.6) (Li et al., 2009) http://www.htslib.org/
FIMO (MEME suite) (Version 4.10.2) (Bailey et al., 2009;
Grant et al., 2011)
http://meme-suite.org/doc/fimo.html
TransDecoder (Version 2.0.1) (Haas et al., 2013) https://github.com/TransDecoder/
TransDecoder/wiki




MISO (Version 0.5.4) (Katz et al., 2010) https://miso.readthedocs.io/en/
fastmiso/index.html
IGV (Version 2.3) (Robinson et al., 2011) https://software.broadinstitute.org/
software/igv/download
R (Version 3.4.3) (R Development Core
Team, 2018)
https://www.r-project.org/
ImageJ (Version 1.50c) NIH https://imagej.nih.gov/ij/
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ImageQuant (Version 5.2) GE Healthcare Life
Sciences
N/A
Image Studio Lite (Version 5.2) LI-COR Biosciences N/A
LightCycler 96 software (Version 1.1.0.1320) Roche N/ACONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for reagents may be directed to and will be fulfilled by the Lead Contact, EugeneMakeyev (eugene.
makeyev@kcl.ac.uk).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines
Human cell lines weremaintained in a humidified incubator at 37C, 5%CO2. HeLa, HCT116, SW620 andMCF7 lineswere cultured in
Dulbecco’s Modified Eagle Medium (DMEM) with high glucose, GlutaMAX and sodium pyruvate (Thermo Fisher Scientific; cat#
31966021) supplemented with 10% Fetal Bovine Serum (FBS; Thermo Fisher Scientific; cat# HYC85), 100 units/ml penicillin and
100 mg/ml streptomycin (13 PenStrep; Thermo Fisher Scientific; cat# 15140122). ARPE-19, WI-38 andWI-38 VA13 cells were main-
tained in advanced DMEM/F12 (Thermo Fisher Scientific; cat# 12634010) supplemented with 5% FBS, 4 mM L-glutamine and 1 3
PenStrep. In some experiments, cells were treated with either CX5461 (300 ng/mL) or 5,6-dichloro-1-d-ribofuranosylbenzimidazole
(DRB; 25 mg/mL) for 5-6 hours. Control samples were treated with DMSO. In transfection experiments, cells were typically seeded
overnight in 1 mL of antibiotic-free medium at 23 105 per well of a 12-well plate. Next morning, 1 mg plasmid was mixed with 3 ml of
Lipofectamine 2000 pre-diluted in 100 ml of Opti-MEM I (Thermo Fisher Scientific; cat# 31985070) and added drop-wise to the cells.
Medium was replaced with PenStrep-containing medium 4 hours post transfection and cells were incubated for further 20-68 hours
(i.e., 24-72 hours post transfection), as required. To activate expression of doxycycline-inducible TRE promoters in pEM1032 (FLAG-
PTBP1), pEM1033 (control plasmid), pML287 (WT CHEK2 minigene), pML291 (mut1 CHEK2 minigene) and pML292 (mut2
CHEK2 minigene), PenStrep-containing medium was additionally supplemented with 2 mg/ml doxycycline (Sigma Aldrich, cat#
D9891). In some experiments, transfected cells were enriched by fluorescence activated cell sorting (FACSAria; BD Biosciences)
based on the expression of an EGFP marker encoded in the experimental plasmid itself (pEM1032 and pEM1033; Figure 6F) or
co-transfected in the form of pEGFP-N3 (Figure S6J). To transfect cells with small nucleic acids, 25-400 pmol of an appropriate
gapmer or 50 pmol of an siRNA was mixed with 3 ml of Lipofectamine RNAiMAX pre-diluted in 100 ml of Opti-MEM I (Thermo Fisher
Scientific) and incubated with cultures for 24 72 hours without changing the medium.
METHOD DETAILS
DNA constructs
Plasmid pBM03 containing a pol-I promoter was kindly provided by Brian McStay (Grob et al., 2014). pcDNA3 and BAC CTD-
2016H21 were from Invitrogen/Thermo Fisher Scientific and pEGFP-N3 was from Clontech. The PNCTR FISH probe BAC was
derived from CTD-2016H21 by replacing a large 47S/45S-containing fragment with an ampicillin resistance cassette derived from
pEM791 (Yap et al., 2012) using recombineering (Lee et al., 2001) (also see Table S4). Other constructs were generated as outlined
in Table S4 using routine molecular cloning techniques and enzymes from New England Biolabs. Maps of all constructs are available
on request.
Nucleocytoplasmic fractionation
Nuclear and cytoplasmic fractions were prepared as described previously (Rio et al., 2010). Briefly, HeLa cells were washed with 13
PBS, scraped off and centrifuged at 15003 g, 4C for 5 min. Cell pellets were resuspended in 4 volumes (relative to the pellet size) of
cell disruption buffer (20 mM Tris-HCl pH 7.5, 10 mM KCl, 1.5 mMMgCl2 and 1 mM DTT) and incubated for 10 min on ice. This was
followed by adding an aliquot of 10%Triton X-100 (Sigma-Aldrich; cat# T8787) to the final concentration of 0.1%and centrifugation at
1500 3 g, 4C for 5 min to separate the cytoplasmic (supernatant) and the nuclear fraction (pellet).
DNA probes
To generate a Northern blot probe, PNCTR-specific PCR product amplified with KAPA HiFi polymerase and PNCTR_F5/PNCTR_R5
primers (Table S5) was labeled using [a-32P]-dCTP and Amersham Megaprime DNA Labeling Systems and purified using a G-50
Column (GE Healthcare; cat# 27533001), as recommended. The probe was denatured at 100C for 5 min and chilled on ice for
2 min immediately before use. Biotin-labeled FISH probe was prepared by incubating 1 mg of the PNCTR FISH probe BAC withMolecular Cell 72, 525–540.e1–e13, November 1, 2018 e5
4 ml of 53Nick Translation reaction buffer, 0.4 ml of 6 mM dNTPmix, 6 ml 1 mMBiotin-16-dUTP in total volume of 20 ml at 18C for 2.5
hours. The reaction was stopped by adding 1 ml each of 20% SDS and 0.5 M EDTA followed by a 10-min incubation at 70C. Labeled
DNA fragments were precipitated with 2.5 volumes of ethanol and 0.1 volumes of 3 M sodium acetate (pH 5.2) using 10 mg of salmon
sperm DNA (Agilent Technologies; cat# 201190) as a carrier. DNA pellet was washed with 70% ethanol and dissolved in nuclease-
free water (Thermo Fisher Scientific, cat# AM9939).
RNA probes
Radiolabeled PNCTR RNA fragments used in electrophoretic mobility shift assays (EMSA) were generated by in vitro transcription
with T7 RNA polymerase (Promega; cat#P2075), as recommended. Briefly, 40 mL reaction mixtures containing 1 3 transcription
buffer, 10 mM DTT, 0.8 unit/ml rRNasin (Promega; cat#N2111), 0.5 mM ATP, 0.5 mM CTP, 0.2 mM GTP, 0.02 mM UTP, 40 mCi of
[a-32P]-UTP, 0.8 mM Ribo m7G Cap analog, 0.8 unit/ml T7 RNA polymerase and 1-2 mg of pEM1380 plasmid linearized with EcoRI
were incubated for 1 h at 37C. Unlabeled probes used in EMSA competition assays were produced by transcribing pEM1380 cut
with EcoRI (PNCTR fragment) or a PCR fragment amplified from pcDNA3 using KAPA HiFi polymerase (Kapa Biosystems;
cat#KK2102) and EMSA_control_F/EMSA_control_R primers (Table S5; control fragment) using the mMESSAGE mMACHINE T7
RNA polymerase kit. In this case, 20 mL reactions containing 1 3 reaction buffer, 7.5 mM each of UTP, ATP and CTP, 1.5 mM
GTP, 6 mM of the cap analog, 1 mL of the T7 enzyme mix and 1-2 mg of an appropriate DNA template were incubated for 3 h at
37C. Both radiolabeled- and unlabeled reactions were treated with 2 units of RQ1 DNase (Promega; cat#M6101) for 15 min at
37C, extracted with acidic phenol-chloroform mixture (1:1), precipitated with 100% ethanol and 3 M sodium acetate, washed
with 70% ethanol and re-suspended with DEPC-treated water. To obtain PNCTR RNA fragment used to prepare a standard curve
for qRT-PCR quantification, 20 ml reactions containing 13 RNAPol reaction buffer, 0.5 mMNTPmix, 1 unit of murine RNase inhibitor
(New England Biolabs; cat# M0314), 5 mM DTT (Thermo Fisher Scientific; cat# 15508013), 100 units of T7 RNA polymerase (New
England Biolabs; cat#M0251S) and 1 mg of pML154 linearized by EcoRI were incubated for 2 hours at 37C. The RNA was then
treated with 2 units of Turbo DNase (Thermo Fisher Scientific; cat#AM2238) for 15 min at 37C and precipitated by adding equal vol-
ume of 7.5 M LiCl followed by incubation at 20C for at least 1 hour. RNA pellets were washed with 70% ethanol and dissolved in
nuclease-free water.
RT-PCR and qRT-PCR
Total RNAswere isolated from cells using TRIzol, as recommended, with an additional acidic phenol-chloroform (1:1) extraction step.
The aqueous phase was precipitated with an equal volume of isopropanol, washed with 70% ethanol and rehydrated in 80 ml of
nuclease-free water. RNA samples were then treated with 4-6 units of Turbo DNase (Ambion) at 37C for 30 min to remove traces
of genomic DNA, extracted with equal volume of acidic phenol-chloroform (1:1), precipitated with 3 volumes of 100% ethanol and
0.1 volume of 3M sodium acetate (pH 5.2), washedwith 70%ethanol and re-suspendedwith nuclease-free water. Reverse transcrip-
tion (RT) was performed using SuperScript IV and random decamer (N10) primers at 50C for 40 min. cDNA samples were analyzed
by regular or quantitative PCR (qPCR). Regular PCR was done using ROCHE Taq DNA polymerase (Sigma-Aldrich, cat#
11596594001) and the RT-PCR products were resolved by electrophoresis in 1%–2% agarose gels. qPCR analyses were carried
out using a Light Cycler96 Real-Time PCR System (Roche) and qPCR BIO SyGreen Master Mix (PCR Biosystems; cat#




























Other RT-(q)PCR primers are listed in Table S5. Unless mentioned otherwise, qRT-PCR signals were normalized to GAPDHmRNA
expression levels (GAPDH_F1/GAPDH_R1; Table S5). In some experiments we used b-actin mRNA as an alternative normalization
control (ACTB_F/ACTB_R; Table S5). To estimate PNCTR abundance, we analyzed total RNA prepared from 4,000 HeLa cells by
qRT-PCR with PNCTR_F1/PNCTR_R1 primers and compared the signal with calibration curve obtained by qRT-PCR amplification
of known amounts of a synthetic PNCTR RNA fragment transcribed from linearized pML154 (see above).
Northern blotting
RNA samples prepared as described in the previous section were separated by electrophoresis in 1.2% agarose gels containing
2.2 M formaldehyde, 40 mM MOPS (pH 7.0), 10 mM sodium acetate and 1 mM EDTA, partially hydrolyzed in 50 mM NaOH/
1.5 M NaCl and transferred overnight to a Hybond N+ membrane in 10 3 SSC as described (Brown et al., 2004). The membrane
was UV-crosslinked (0.12 J/cm2), stained with methylene blue to visualize the 28S and 18S rRNAs, washed in 0.2 3 SSC/1%
SDS and blocked in ExpressHyb (Clontech; cat# 636831) at 68C for 1 hour. Hybridization with heat-denatured DNA probe was
done in ExpressHyb at 68C for 2 hours. The membrane was washed twice in 2 3 SSC, 0.05% SDS at 68C and twice in 0.1 3
SSC, 0.1% SDS at 50C, 15 min each wash. The membrane was then dried and radioactive bands were visualized using a Typhoon
Trio Variable Mode Imager (GE Healthcare).
Electrophoretic Mobility Shift Assays (EMSA)
EMSA was done as described previously (Rio, 2014; Zheng et al., 2012), with minor modifications. Briefly, 20 mL mixtures containing
20mMHEPES-KOH (pH 7.9), 100mMKCl, 2.2mMMgCl2, 0.5mMDTT, 0.2mMEDTA, 20% (w/v) glycerol, and 50 nM [a-
32P]-labeled
PNCTR fragment were incubated for 30 min at 30C with 0-1 mM purified recombinant PTBP1 or equal amounts of bovine serum al-
bumin (BSA; Sigma-Aldrich; cat# 10711454001). For competition assays, 0-4 mM of unlabeled RNA probes were pre-incubated with
75 nM of PTBP1 protein for 30 min at 30C before adding 50 nM of [a-32P]-PNCTR fragment probe and continuing the incubation for
another 30 min. The RNA-protein complexes were separated by electrophoresis in 6% native polyacrylamide gels and the visualized
using a Typhoon Trio Variable Mode Imager (GE Healthcare Life Sciences).
RNA immunoprecipitation (RIP)
Prior to cell lysis, 2.4 mg of Dynabeads Protein G (i.e., 80 mL of the original 30 mg/ml suspension; Thermo Fisher Scientific; cat#
10004D) were washed with 1 3 PBS and 0.02% Tween-20, incubated with 6 mg of either PTBP1-specific antibody or non-immune
mouse IgG in 500 ml of 13 PBS/0.02% Tween-20 at room temperature for 1 hour with rotation and washed with 500 ml of 13 PBS/
0.02% Tween-20. To facilitate buffer exchange, beads were captured using a DynaMag-2 magnetic stand (Thermo Fisher Scientific,
cat# 12321D). HeLa cells were grown in 15 cm dishes to 80%–90% confluency, washed once with ice-cold 13 PBS, and scraped off
in 2 ml/dish of ice-cold 10 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.5% NP40, 100 units/ml rRNasin (Promega; cat# N2111) and the
recommended amount of cOmplete EDTA-free protease inhibitor cocktail (Sigma-Aldrich; cat# 04693132001). The lysates were
incubated on ice for 30min with occasional agitation and cleared bymicro-centrifugation at 21,1303 g for 3min at 4C. 1mL aliquots
of the supernatant were mixed with 2.4 mg of drained antibody-loaded Dynabeads Protein G and rotated at 4C for 150 min. Beads
were subsequently washed with four changes of 13 PBS/0.02% Tween-20, 250 ml each time. RNAs interacting with the beads were
eluted with 1 mL of TRIzol, as recommended, and precipitated from the aqueous phase with 0.5 mL of isopropanol and 20 mg of
purified glycogen (Sigma-Aldrich; cat# 10901393001) used as a carrier. RNA pellets were washed with 70% ethanol, rehydrated
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CLIP/qRT-PCR
UV-crosslinking and immunoprecipitation of RNA-protein complexes was carried out as described (Huppertz et al., 2014) with some
modifications. HeLa cells were seeded into 10-cm dishes at43 106 cells/dish and allowed to attach overnight. The cells were then
transfected with 400 nMgmControl or gmPNCTR for 24 hours, washed oncewith 10mL of ice-cold 13PBS and irradiated with UV-C
(Stratalinker 1800; 150mJ/cm2; in 4mL 13PBS on ice). PBSwas aspirated and the cells were scraped off in 1mL of CLIP lysis buffer
[50 mM Tris-HCl, pH7.4, 100mMNaCl, 1 mMMgCl2, 0.1 mMCaCl2, 1% Igepal CA-630 (Sigma Aldrich, cat# I8896), 0.1%SDS, 0.5%
sodium deoxycholate and the recommended amount of cOmplete EDTA-free protease inhibitor cocktail]. The lysates was then son-
icated using Bioruptor (Diagenode; low intensity settings, 5 cycles of 30 s on/ 30 s off; 4C), incubated on ice for 5min and treatedwith
4 ml Turbo DNase (Ambion; 2 units/ml) and 1 ml of murine RNase inhibitor (New Englands Biolabs; 40 units/ml) for 7 min at 37C with
shaking at 1100 rpm (Thermomixer compact, Eppendorf). To fragment RNA, 1 unit of RNase I (Thermo Fisher Scientific) was then
added to the tubes and the shaking was continued for another 3min at 37C. The lysates were chilled on ice for 3min and centrifuged
at 21,130 3 g for 15 min at 4C to remove debris.
Beads for pre-clearing the lysates and immunoprecipitation were prepared as follow: 250 ml protein G dynabeads was pre-blocked
with 0.1% BSA and 0.2 mg/ml yeast tRNA in 1 mL CLIP lysis buffer overnight at 4C with rotation. Pre-blocked beads were washed
once with CLIP lysis buffer and resuspended in 500 ml CLIP lysis buffer. Of the 500 ml, two 50-ml aliquots were set aside for pre-
clearing the gmControl and the gmPNCTR lysates and four 100-ml aliquots were used for immunoprecipitations. Two 100-ml aliquots
were incubated with 8 mg of the PTBP1-specific antibody and the other two, with 8 mg of the IgG control for 1 hour at room temper-
ature with rotation. Antibody-conjugated beads were then washed once with 800 ml CLIP lysis buffer before proceeding to the
next step.
The gmControl and the gmPNCTR lysates prepared as explained above were pre-cleared by incubating each of them with pre-
blocked beads for 30 min at 4C. To prepare input RNA samples, 10% aliquots of the pre-cleared lysates were set aside at this point
and incubated with 1% SDS and 1 mg/ml of proteinase K (Thermo Fisher Scientific; Cat: EO0491) at 55C for 30 min with shaking at
1100 rpm. The aliquots were then topped up with nuclease free water to 200 ml and extracted with 600 ml Trizol LS (Thermo Fisher
Scientific; cat#10296010). After separating the aqueous and organic phases by the addition of 160 ml chroloform, we collected the top
half of the aqueous phase, extracted it once with 300 ml of acidic phenol:chloroform (1:1) and once with 300 ml chloroform and precip-
itated with 8 mg glycogen, 0.3 M NaOAc, pH 5.2 and 1 volume of 100% isopropanol at20C overnight. The RNA pellets were finally
washed with 70% ethanol and dissolved in nuclease-free water.
The remaining 90% of the pre-cleared gmControl and the gmPNCTR lysates were split into two equal aliquots, which were incu-
bated with PTBP1- and IgG-conjugated beads, respectively, overnight at 4C with rotation. Next morning, the beads were washed
three times with ice-cold 50mMTris-HCl, pH 7.4, 1MNaCl, 1 mMEDTA, 1% Igepal CA-630, 0.1%SDS, 0.5% sodium deoxycholate,
twice with ice-cold 20 mM Tris-HCl, pH 7.4, 10 mMMgCl2, 0.2% Tween-20 and once with proteinase K buffer (100 mM Tris-HCl, pH
7.4, 50 mM NaCl, 10 mM EDTA). Immunoprecipitated RNA fragments were then eluted by incubating the beads with 200 ml of pro-
teinase K buffer additionally supplementedwith 1%SDS and 1mg/ml of proteinase K (Thermo Fisher Scientific; Cat: EO0491) at 55C
for 30 min. The mixtures were extracted once with 200 ml of acidic Phenol: chloroform (1:1) and once with 200 ml chloroform and
precipitated with 20 mg glycogen, 0.1 M NaCl, 0.3 M NaOAc, pH 5.2 and 3 volumes of 100% ethanol at 80C for 1 hour. The
RNA pellets were washed once with 70% ethanol, resuspended in nuclease free-water and analyzed alongside the input samples





ACTB ACTB_F/ACTB_RCAP trapper assays
To test if the 50 end of PNCTR was modified by a guanosine triphosphate-based cap, we used a modified version of the CAP trapper
protocol (Carninci et al., 1996). We first oxidized vicinal 20,30-diol groups present in most caps and 30-terminal RNA nucleotides by
incubating 12 mg of total RNA in 50 ml of 66 mM NaOAc (pH 5.2) and freshly prepared 5 mM sodium periodate for 1h on ice in the
dark. A negative control reaction was set up in a similar manner but without sodium periodate. The oxidized and control RNAs
were precipitated with 3.3 mL of 7.5 M LiCl, 1 mL of 10% SDS and 50 ml of isopropanol for 30 min at 20C and centrifuged at
21,130 3 g for 15 min at 4C. The RNA pellets were washed once with 70% ethanol and dissolved in 50 ml of nuclease-free water.
The solutions were then supplemented with 5 mL of 1M NaOAc (pH 6.1), 5 mL of 10% SDS and 150 mL of freshly dissolved 10 mM
biocytin hydrazide and incubated overnight at room temperature in the dark to biotinylate periodate-oxidized groups. The RNAs
were precipitated from biotynylation mixtures with 5 mL of 5 M NaCl, 75 mL of 1 M NaOAc (pH 6.1) and 725 mL of 100% ethanol, incu-
bated on ice for 1 hour, spun at 21,1303 g for 15min at 4C, washed oncewith 70%ethanol, once with 80%ethanol and dissolved in
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The RNAs were used as templates for first-strand cDNA synthesis using SuperScript IV and N10 primers as described above. The
RT reactions (40 ml) were then supplemented with 20 mL of 100 mM Tris-HCl (pH 7.5), 1 M NaCl and 50 mM EDTA and 140 mL of
nuclease-free water and treated with 250 units of RNase I for 30 min at 37C to digest RNA sequences that are not base-paired
with cDNA. The RNA-cDNA duplexes were precipitated by 5 mL of 10% SDS, 5 mL of 5 M NaCl, 75 mL of 1 M NaOAc (pH 6.1),
0.5 mL of glycogen (20 mg/ml) and 720 mL of 100% ethanol and incubated for 1 hour at20C. The RNA-cDNA duplexes were washed
oncewith 70%ethanol, dissolved in 55 ml of ice-cold Elution buffer (10mMTris-HCl, pH 7.5 and 0.1mMEDTA) andmixedwith 55 ml of
2 3 Wash/Binding buffer (1 M NaCl, 40 mM Tris-HCl, pH 7.5, 2 mM EDTA) before proceeding to the next step.
At this point, cDNA-RNA duplexes corresponding to the 50 ends of capped RNAs should be covalently modified by biotin groups in
the periodate-oxidized/biocytin hydrazide-treated sample (but not in the negative control). To capture these biotinylated duplexes,
we used hydrophilic streptavidin magnetic beads (New England Biolabs, cat#S1421S) prepared in the following manner. For each
RNA-cDNA sample, 1 mg (250 ml) of Streptavidin beads was washed twice with 500 ml of Wash/Binding buffer (0.5 M NaCl,
20 mM Tris-HCl, pH 7.5, 1 mM EDTA). The beads were blocked with 100 ml of Wash/Binding buffer containing 10 mg/ml of yeast
tRNA at room temperature for 1 hour and washed twice with 500 ml of Wash/Binding buffer. The beads were then combined with
the RNA-cDNAs mixtures prepared as described above and incubated for 10 min at room temperature with occasional agitation.
The beads were washed twice with 500 ml Wash/Binding buffer at room temperature, once with ice-cold Low-Salt Wash buffer
(0.15 M NaCl, 20 mM Tris-HCl, pH 7.5 and 1 mM EDTA), and twice with ice-cold Elution buffer. The cDNAs were then eluted in
125 ml of Elution buffer at 96C for 5min followed by quickly separating the eluate from the beads using a DynaMag-2magnetic stand.
The elution step was repeated once and the two eluates containing cDNA copies of capped RNAs were pooled, extracted with a 1:1
mixture of Tris-HCl-equilibrated phenol:chloroform and precipitated with 3 volumes of 100% ethanol, 0.1 volume of 3 M sodium ac-
etate (pH 5.2) and 0.6 ml of 20 mg/ml glycogen. The cDNAs were rehydrated in nuclease-free water and analyzed by qPCR with the





U6 U6_F/U6_RAnalysis of RNA polyadenylation status
Polyadenylated RNA fraction was isolated using the MagJET mRNA Enrichment Kit (Thermo Fisher Scientific, cat# K2811), as rec-
ommended. Briefly, 50 mg of total HeLa RNA was incubated at 65C for 5 min and chilled on ice for 2 min. The RNA was then mixed
with pre-washed MagJET oligo(dT) beads (50 ml of beads washed twice with 50 ml hybridization buffer and resuspended in 100 ml of
hybridization buffer) and incubated at room temperature with gentle agitation for 5 min followed by separation of the beads from the
supernatant using a DynaMag-2 magnetic stand. The supernatant containing the non-polyadenylated RNA fraction (‘‘flow-through’’)
was collected and the beads were washed 3 times with the wash buffer. The beads were then resuspended in 50 ml of nuclease-free
water, heated at 60C for 2 min and then cooled to room temperature for 5 min. This was followed by the addition of 50 ml of hybrid-
ization buffer and a 5-min incubation at room temperature to recapture polyadenylated RNAs. The beads were then washed twice
with the wash buffer, resuspended in 50 ml nuclease-free water, incubated at 60C for 2min and then immediately separated from the
eluate containing polyadenylated RNAs using DynaMag-2. Both the flow-through and the oligo(dT) bead-bound fractions were then








HeLa cells were plated overnight in a 12-well plate at 23 105/well in 1 mL of DMEMwith 10% FBS without antibiotics. Next morning,
cells were transfectedwith 25 pmol/well of an appropriate gapmer (QIAGEN) that wasmixedwith 3 ml of Lipofectamine RNAiMAX pre-
diluted in 100 ml of OPTI-MEM. Total RNAs were extracted 24 hours post transfection using TRIzol and a PureLink RNA Mini Kit with
on-column PureLink DNase (Thermo Fisher Scientific; cat# 12185010) treatment, according to the manufacturer’s recommenda-
tions. The RNAs were eluted in nuclease-free water, QC’d (Bioanalyzer RIN = 9.8) and hybridized with oligo(dT) magnetic beadsMolecular Cell 72, 525–540.e1–e13, November 1, 2018 e9
to isolate the poly(A) RNA fraction used for subsequent library preparation steps. Stranded mRNA sequencing libraries were pre-
pared using the TruSeq Stranded mRNA Library Preparation Kit (Illumina cat## RS-122-2101 and RS-122-2102). Purified libraries
were qualified on an Agilent Technologies 2200 TapeStation using a D1000 ScreenTape assay (cat## 5067-5582 and 5067-5583).
The molarity of adaptor-modified molecules was defined by quantitative PCR using the Kapa Library Quant Kit (Kapa Biosystems;
cat# KK4824). Individual libraries were normalized to 10 nM and equal volumes were pooled in preparation for Illumina sequence
analysis. Sequencing libraries (25 pM) were chemically denatured and applied to an Illumina HiSeq v4 single read flow cell using
an Illumina cBot. Hybridized molecules were clonally amplified and annealed to sequencing primers with reagents from a HiSeq
SR Cluster Kit v4-cBot (Illumina; cat# GD-401-4001). Following transfer of the flowcell to a HiSeq 2500 instrument (Illumina; cat##
HCSv2.2.38 and RTA v1.18.61), a 50 cycle single-read sequence run was performed using HiSeq SBS Kit v4 sequencing reagents
(Illumina; cat# FC-401-4002). All library preparation and sequencing steps were carried out by the Huntsman Cancer Institute High-
Throughput Genomics facility, University of Utah, USA.
Immunoblotting
Cells were washed three times with ice-cold 13 PBS and proteins were extracted using RIPA lysis buffer (Santa Cruz Biotechnology;
cat# sc-364162) supplemented with 1 mM PMSF and the recommended amount of cOmplete EDTA-free protease inhibitor cocktail.
Protein concentrations were determined using a Pierce BCA Protein Assay Kit. Protein samples (10-20 mg) were then incubated at
95C for 5 min in 13 Laemmli sample buffer (50 mM Tris-HCl, pH 6.8, 100 mM DTT, 2% SDS, 10% glycerol and 0.1% bromophenol
blue), separated by 4%–20% gradient SDS-PAGE (Bio-Rad; cat# 4561096), electrotransferred to nitrocellulose membranes and
analyzed using appropriate primary and secondary antibodies. Fluorescent immunoblot signals were detected using Odyssey imag-
ing system (LI-COR Biosciences). Enhanced chemiluminescence (ECL) detection was done using reagents from Thermo Fisher Sci-
entific (ECL kits cat## 32106 or 11546345 and GE Healthcare Amersham Hyperfilm cat# 10607665). Protein band intensities were
quantified using LI-COR Image Studio software (LI-COR Biosciences). To estimate PTBP1 abundance, lysates from 1 3 105 HeLa
cells were analyzed by immunoblotting alongside known amounts of His-tagged PTBP1 purified from bacteria.
Immunofluorescence combined with RNA fluorescence in situ hybridization (IF-FISH)
HeLa cell cultures were grown on 18 mm round coverslips pre-coated with 50 mg/ml poly-D-lysine. The coverslips were washed with
13 PBS, incubated with 100mMNaCl, 300mM sucrose, 10mMPIPES (pH 7.8), 3 mMMgCl2, 0.5% Triton X-100, 80 units/ml murine
RNase inhibitor (New England Biolabs; cat# M0314) for 4 min on ice and fixed with 4% paraformaldehyde (Ted Pella; cat# 18501) for
15 min at room temperature. The coverslips were then washed three times with 13 PBS, blocked with IF-FISH blocking buffer [13
PBS containing 0.5% BSA (Thermo Fisher Scientific; cat# BP8805) and 0.2% Tween-20 (Sigma-Aldrich; cat# P9416)] for 30 min at
room temperature and then incubated with appropriate primary antibodies in the IF-FISH blocking buffer additionally containing
20 units/ml murine RNase inhibitor (New England Biolabs; cat# M0314) for 16-18 hours at 4C. Following three washes with 1 3
PBS the coverslips were then incubated with corresponding Alexa Fluor-conjugated secondary antibodies for 1 hour at room tem-
perature. The coverslips were then washed three times with 1 3 PBS and post-fixed with 4% paraformaldehyde for 15 min at room
temperature, washed three times with 1 3 PBS and used for subsequent RNA-FISH staining.
To perform RNA-FISH, 70 ng of biotinylated PNCTR FISH probe prepared as described above was co-precipitated with 5 mg hu-
man Cot1-DNA (Thermo Fisher Scientific; cat# 15279011), 5 mg salmon sperm DNA and 10 mg yeast tRNA (Sigma-Aldrich; cat#
R8508) using 3 volumes of ethanol and 0.1 volume of 3 M sodium acetate (pH 5.2). The probe pellet was washed with 70% ethanol,
dissolved in 15 ml of 100% formamide, denatured at 65C for 10 min and chilled on ice. The probe was then mixed with 15 ml of 23
FISH hybridization buffer [0.4% BSA, 4 3 SSC, 20% dextran sulfate (Sigma-Aldrich, cat# D8906), 40 mM Ribonucleoside Vanadyl
Complex (Promega, cat# S1402S)] and incubated with cells overnight at 37C. The coverslips were then washed once with 50%
formamide and 2 3 SSC at 37C, once with 2 3 SSC at 37C and once with 1 3 SSC at room temperature, 15 min each wash,
and once in 4 3 SSC for 1-2 min. This was followed by incubating the coverslips with Alexa Fluor 647-conjugated streptavidin in
4 3 SSC, 0.8% BSA and 0.8 units/ml murine RNase inhibitor (New England Biolabs; cat# M0314) for 1 hour at 37C, and washing
them at room temperature once with 4 3 SSC, once with 4 3 SSC and 0.1% Triton X-100 and once with 4 3 SSC, 10 min each
wash. The coverslips were finally stained with 0.5 mg/ml DAPI and mounted onto microscope slides using ProLong Gold antifade re-
agent (Thermo Fisher Scientific, cat# P36934). A similar protocol was used for formalin-fixed paraffin-embedded tissue sections
except the IF part was replaced by dewaxing, rehydration, and permeabilization steps (https://biosearchassets.blob.core.
windows.net/assets/bti_stellaris_protocol_ffpe_tissue.pdf). Images were taken using an LSM 800 confocal microscope (Zeiss)
equipped with a 63 3 Plan- Apochromat, 1.4 NA oil immersion objective. To quantify PNCTR and PTBP1 dots, Z stacks were taken
at 0.35 mm intervals. Maximum intensity projections of the Z series were thresholded, converted to a binary format and used as an
input for the ‘‘Analyze Particles’’ application of ImageJ.
Immunofluorescence combined with single-molecule RNA fluorescence in situ hybridization (IF-smFISH)
HeLa cell cultures were grown on 18 mm round coverslips and fixed with 4% paraformaldehyde as described in the IF-FISH section
above. The coverslips were then washed three times with 1 3 PBS, blocked with IF-smFISH blocking buffer [1 3 PBS containinge10 Molecular Cell 72, 525–540.e1–e13, November 1, 2018
0.5% BSA (Thermo Fisher Scientific; cat# BP8805)] for 30 min at room temperature and incubated with appropriate primary anti-
bodies in the IF-smFISH blocking buffer additionally containing 20 units/ml murine RNase inhibitor (New England Biolabs;
cat#M0314) for 1 hour at room temperature. Following three washeswith 13PBS, the coverslips were incubated with corresponding
Alexa Fluor-conjugated secondary antibodies for 1 hour at room temperature. The coverslips were then washed three times with 13
PBS and post-fixed with 4% paraformaldehyde for 10 min at room temperature, washed three times with 13 PBS and used for sub-
sequent RNA-smFISH staining.
The coverslips were washed oncewithWash Buffer A [20%Stellaris RNA FISHWash Buffer A (Biosearch Technologies; cat# SMF-
WA1-60) and 10% formamide in nuclease-free water] for 5 min at room temperature, and incubated with Stellaris RNA FISH Hybrid-
ization Buffer (Biosearch Technologies; cat# SMF-HB1-10) containing 10% formamide and 125 nM of the PNCTR-specific Stellaris
probe in the dark at 37C overnight. The coverslips were then washed once with Wash Buffer A and once with Wash Buffer A con-
taining 0.1 mg/ml DAPI, both washes in the dark at 37C for 30min, andmounted ontomicroscope slides using ProLongGold antifade
reagent.
Images were taken and maximum intensity projections produced as described in the IF-FISH section. Diffraction-limited single-
molecule signals were selected manually and their background-subtracted intensities were quantified using ImageJ. The total num-
ber of PNCTR molecules per nucleus was then estimated by dividing the overall PNCTR signal intensity by the median intensity of
single-molecule signals. PTBP1 sequestration was estimated as a fraction of total nuclear PTBP1 minus cytoplasmic background
co-localizing with the PNCTR signal.
Clonogenic assays
HeLa cells were transfected with 25-400 nM of gmControl or gmPNCTR as described above. 24 hours post transfection cells were
trypsinized, re-plated into 6-well plates at 100-10,000 cells/well and incubated for 10 days changing the medium every 2-3 days. Cell
colonies were stained with 0.1% methylene blue in 50% (v/v) methanol for 1 hour at room temperature, washed with water and air-
dried. Confluency of each well was then quantified using ImageJ.
Cell viability assays
HeLa cells were plated into 96-well plates at 1 3 104/well. Next morning, the cells were treated with 25-400 nM gmControl or
gmPNCTR for up to 72 hours. Cell viability in the transfected wells was assayed using PrestoBlue Cell Viability Reagent according
to the manufacturer’s recommendation. Briefly, 0.1 volume of PrestoBlue reagent was added directly to culture medium and incu-
bated at 37C for 30 min. After incubation, absorbance reads were taken at both 570 nm and 630 nm (as a reference wavelength)
using an MRX II microplate reader (Dynex Technologies). The experimental values were acquired by normalization of 570 nm to
630 nm to plot the graph. Two independent experiments were carried out with each condition tested in triplicate (i.e., 6 repeats
in total).
Bioinformatics
To predict transcripts with multiple RBP motifs, ENCODE RNA-seq reads for 5 commonly used human cell lines, A549, HeLa
(clone S3), HepG2, K562 and MCF7 (see the list of Deposited Data above) were aligned with TopHat2 using a GRCh38.p3-based
Bowtie2 genome index and a GENCODE v23 GTF human transcriptome annotation file, as follows:




BAM files generated by TopHat2 were used for subsequent GENCODE v23 reference-guided transcriptome assembly done using
StringTie with relaxed muli-mapping read settings:
stringtie -p <n_threads> -M 1 -o <out_gtf_file> \
-G <GENCODEv23_transcriptome_gtf_file> \
<TopHat2_accepted_hits_bam_file>
GTF files produced by StringTie were merged into a single transcriptome file:




We applied two filters to the merged transcriptome file to reduce the incidence of false positives. First, we removed all tran-
scripts that did not overlap known transcribed sequences (a combination of exonic ranges in GENCODE v23 GTF and mRNAMolecular Cell 72, 525–540.e1–e13, November 1, 2018 e11
and EST sequences downloaded from https://genome.ucsc.edu/cgi-bin/hgTables) at least by one nucleotide in a strand-specific
manner:
bedtools intersect -s -sorted -split -u \
-a <sorted_bed12_for_merged_transcriptome> \
-b <sorted_bed6_for_GENCODEv23_mRNA_EST_exons>
Second, we discarded transcripts expressed at relatively low levels across the 5 cancer lines (median < 0.1 TPM) according to
Kallisto, a program allocating RNA-seq reads (including multi-mapping ones) to their likely RNA origins using an expectation-maxi-
mization algorithm:
kallisto quant -i <Kallisto_transcriptome_index> \
-o <out_dir> -b 1 PE_reads_1.fastq PE_reads_2.fastq
Novel transcripts passing the two above filters and all the GENCODE v23 transcripts were combined into a single transcriptome
annotation and used to calculate the occurrence of known RBPmotifs downloaded as position weight matrices (PWMs) from CisBP-
RNA (http://cisbp-rna.ccbr.utoronto.ca/; Homo sapiens, November 23, 2015 freeze). PWM matches were identified using the FIMO
package of the MEME suite and a final transcriptome-based Markov background file:
fasta-get-markov <final_transcriptome_fasta_file> markov1.b -norc -m 1
fimo–no-qvalue–norc–thresh 0.001–motif-pseudo 0.1 \
–max-stored-scores 100000000–bgfile markov1.b–oc <out_dir> \
<MEME_formatted_PWM_file> <final_transcriptome_fasta_file>
In addition to imposing the FIMO threshold of p < 0.001, we discarded matches with < 0.85 fit to the maximally achievable PWM
score as described (Pan and Phan, 2008). For each PWM, we calculated z-scores for numbers and densities of qualifying matches in
R. Candidate transcripts with both z-scoresR 5 (n = 251) were retained for further analyses. Of these, 96were classified as ‘‘unknown
intergenic RNAs’’ (StringTie class code ‘‘u’’; Table S1). hg38-specific STRswere downloaded from https://genome.ucsc.edu/cgi-bin/
hgTables (Simple Tandem Repeats by TRF), merged into a bed file containing non-overlapping intervals and intersected with strRNA
and control sequences using Bedtools. The longest ORF was predicted for each strRNA by TransDecoder using the entire cancer
cell-specific transcriptome with median expression R 0.1 TPM and all known protein-coding transcripts from GENCODE v23 as
controls.
Possible overlap of strRNAs with lncRNA entries from the LNCipedia database (https://lncipedia.org/downloads/
lncipedia_5_0_hc_hg38.bed) was analyzed using Bedtools:
bedtools intersect -s -split -wo -f 0.25 \
-a <strRNA_bed_file> -b <lncipedia_bed_file>
To compare splicing events regulated by PNCTR and PTBP1/PTBP2, we analyzed corresponding datasets generated in this study
(ArrayExpress; E-MTAB-6529) and published previously (Ling et al., 2016) using two alternative approaches. In the first approach, we
identified regulated skipped exons by processing RNA-seq data using ExpressionPlot and hg18-derived annotation files provided
with this package. The coordinates of regulated exons were mapped to the GRCh38/hg38 assembly using the USCS Genome
Browser liftOver program (https://genome.ucsc.edu/cgi-bin/hgLiftOver). Alternatively, RNA-seq reads were aligned to the hg19 as-
sembly using HISAT2 with a premade index (ftp://ftp.ccb.jhu.edu/pub/infphilo/hisat2/data/hg19.tar.gz) and coordinates of known
splice sites extracted from an hg19 transcriptome annotation file (http://genes.mit.edu/burgelab/miso/annotations/ucsc_tables/
hg19/ensGene.gff3). After converting HISAT2-generated SAM files into sorted and indexed BAM files with Samtools we identified
regulated exonic events using MISO and annotations for skipped exons, mutually exclusive exons and alternative 50 and 30 splice
sites downloaded from http://genes.mit.edu/burgelab/miso/annotations/ver2/miso_annotations_hg19_v2.zip. In both cases, statis-
tical significance of overlaps between different sets of regulated exons was calculated by analyzing a contingency table with regu-
lated and non-regulated or up- and downregulated categories using Fisher’s exact test.
To analyze genome-wide binding patterns of pol I, publicly available ChIP-seq data [(Sanij et al., 2015); GEO: GSM1544525] for the
hTERT-immortalized humanmammary epithelial cell line (HMEC) were aligned to the GRCh38.p3 genome using Bowtie2 with default
parameters. After removing duplicated reads and reads with alignment quality AS < 2, pol I genomic distribution was visualized
using Integrative Genomics Viewer (IGV). BED files with PTBP1-specific CLIP-seq and iCLIP clusters for HeLa cells were
downloaded from previously published studies [(Xue et al., 2009); GEO: GSE19323; (Coelho et al., 2015; Haberman et al., 2017);
ArrayExpress: E-MTAB-3108; https://github.com/jernejule/non-coinciding_cDNA_starts/blob/master/HeatMaps_of_PTBP1-motifs_
around-eCLIP-iCLIP-irCLIP-clusters-PTBP1/data/PTBP1-iCLIP1.3nt.peaks.3nt.clusters.bed.gz] and mapped to GRCh38/hg38
using the USCS Genome Browser liftOver tool. To identify high-confidence PTBP1-RNA interaction sites, we discarded clusters not
intersectable within the monomeric and dimeric duplicates of the CLIP-seq dataset and merged the remaining monomeric and dimeric
clusters into a single track. The iCLIP clusters were used without further modifications.e12 Molecular Cell 72, 525–540.e1–e13, November 1, 2018
QUANTIFICATION AND STATISTICAL ANALYSES
All statistical procedures were carried out using Microsoft Excel and R and, unless stated otherwise, experimental data were
averaged from at least three experiments and shown with error bars representing SD. Data obtained from qRT-PCR, immunoblot
quantifications, colony formation and cell viability assays were typically analyzed using a two-tailed Student’s t test assuming un-
equal variances. RT-PCR and immunoblot quantification data for series of independently generated pairs of control and experimental
treatments were analyzed using paired t test. Immunofluorescence data were analyzed using a two-sided Kolmogorov-Smirnov (KS)
test. Numbers of experimental replicates and p values are provided in the figures.
DATA AND SOFTWARE AVAILABILITY
RNA-seq data generated in this study are available from ArrayExpress: E-MTAB-6529.Molecular Cell 72, 525–540.e1–e13, November 1, 2018 e13
